Top

Published in:

Open Access 01-11-2013 | Original Communication

Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis

Authors: Lisa Kaerst, Andre Kuhlmann, Dirk Wedekind, Katharina Stoeck, Peter Lange, Inga Zerr

Published in: Journal of Neurology | Issue 11/2013

Abstract

Vascular factors are thought to contribute to the development of disease pathology in neurodegenerative dementia such as Alzheimer’s disease (AD). Another entity, called vascular dementia (VaD), comprises a less defined group of dementia patients having various vascular diseases that especially emerge in the elderly population and require valid options for examination and differential diagnosis. In the context of a retrospective study, we analyzed the cerebrospinal fluid (CSF) biomarkers t-tau, p-tau and Aß42 of a total of 131 patients with AD (n = 47), mild cognitive impairment (MCI) (n = 22), VaD (n = 44) and stroke (n = 18). We found a remarkable alteration in CSF biomarker profile in AD, VaD and in acute ischemic events. CSF profile in AD patients was altered in a very similar way as in stroke patients, without statistical differences. In stroke, increase depend largely on size and duration after the initial event. Total tau levels were useful to differ between VaD and stroke. Aß42 decreased in a similar way in AD, VaD and stroke and had a trend to lower levels in MCI but not in controls.

McKhann G, Drachmann D, Folstein M, Katzmann R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease. Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force of Alzheimer’s disease. Neurology 34:934–944CrossRef

Biagioni MC, Galvin JE (2011) Using biomarkers to improve detection of Alzheimer’s disease. Neurodegener Dis Manag 1:127–139PubMedCrossRef

Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K (2001) Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297:187–190PubMedCrossRef

Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, Blennow K (2000) Cerebrospinal fluid markers for Alzheimer’s disease evaluated after acute ischemic stroke. J Alzheimers Dis 2:199–206PubMed

Lanari A, Parnetti L (2009) Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting. Sci World J 9:961–966CrossRef

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S (2011) Assessment of cerebrospinal fluid (CSF) beta-amyloid (1–42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer’s disease (AD) and other dementia at Siriraj Hospital, Thailand. J Med Assoc Thai 94(Suppl 1):S77–S83PubMed

Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A (2011) Screening for new biomarkers for subcortical vascular dementia and Alzheimer’s disease. Dement Geriatr Cogn Dis Extra 1:31–42PubMedCrossRef

Pluta R, Jolkkonen J, Cuzzocrea S, Pedata F, Cechetto D, Popa-Wagner A (2011) Cognitive impairment with vascular impairment and degeneration. Curr Neurovasc Res 8:342–350PubMedCrossRef

Paraskevas GP, Kapaki E, Papageorgiou SG, Kalfakis N, Andreasou E, Zalonis I, Vassilopoulos D (2009) CSF biomarker profile and diagnostic value in vascular dementia. Eur J Neurol 16:205–211PubMedCrossRef

10.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385–393PubMedCrossRef

11.

Schmidtke K, Hermeneit S (2008) High rate of conversion to Alzheimer’s disease in a cohort of amnestic MCI patients. Int Psychogeriatr 20:96–108PubMedCrossRef

12.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228–234PubMedCrossRef

13.

Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O (2010) Evaluation of CSF biomarkers as predictors of Alzheimer’s disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis 21:1119–1128PubMed

14.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of beta-amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69:98–106PubMedCrossRef

15.

Zieren N, Duering M, Peters N, Reyes S, Jouvent E, Herve D, Gschwendtner A, Mewald Y, Opherk C, Chabriat H, Dichgans M (2013) Education modifies the relation of vascular pathology to cognitive function: cognitive reserve in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurobiol Aging 34:400–407PubMedCrossRef

16.

Pluta R, Ulamek M, Jablonski M (2009) Alzheimer’s mechanisms in ischemic brain degeneration. Anat Rec (Hoboken) 292:1863–1881CrossRef

17.

Wen Y, Yang S, Liu R, Simpkins JW (2004) Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. Brain Res 1022:30–38PubMedCrossRef

18.

Zheng GQ, Wang XM, Wang Y, Wang XT (2010) Tau as a potential novel therapeutic target in ischemic stroke. J Cell Biochem 109:26–29PubMed

19.

Bielewicz J, Kurzepa J, Czekajska-Chehab E, Stelmasiak Z, Bartosik-Psujek H (2011) Does serum Tau protein predict the outcome of patients with ischemic stroke? J Mol Neurosci 43:241–245PubMedCrossRef

20.

Bitsch A, Horn C, Kemmling Y, Seipelt M, Hellenbrand U, Stiefel M, Ciesielczyk B, Cepek L, Bahn E, Ratzka P, Prange H, Otto M (2002) Serum tau protein level as a marker of axonal damage in acute ischemic stroke. Eur Neurol 47:45–51PubMedCrossRef

21.

Wunderlich MT, Lins H, Skalej M, Wallesch CW, Goertler M (2006) Neuron-specific enolase and tau protein as neuro biochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 108:558–563PubMedCrossRef

22.

Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/American stroke association. Stroke 42:2672–2713PubMedCrossRef

Title: Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis
Authors: Lisa Kaerst
Andre Kuhlmann
Dirk Wedekind
Katharina Stoeck
Peter Lange
Inga Zerr
Publication date: 01-11-2013
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 11/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-013-7047-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2013

Amyotrophic lateral sclerosis: an update on recent genetic insights

The Addenbrooke’s Cognitive Examination-Revised accurately detects cognitive decline in Huntington’s disease

Progressive ataxia with oculo-palatal tremor and optic atrophy

Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types

Fulminant toxic shock syndrome following rituximab therapy in an 11-year-old boy

Central nervous system angiitis in Hodgkin’s disease